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Abstract
Pain-related sensitization and synaptic plasticity in the central nucleus of the amygdala (CeA)
depend on the endogenous activation of NMDA receptors and phosphorylation of the NR1 subunit
through a PKA-dependent mechanism. Functional NMDA receptors are heteromeric assemblies of
NR1 with NR2A-D or NR3A, B subunits. NMDA receptors composed of NR1 and NR2B subunits
have been implicated in neuroplasticity and are present in the CeA. Here we used a selective NR2B
antagonist (Ro-256981) to determine the contribution of NR2B-containing NMDA receptors to
pain-related sensitization of CeA neurons. Extracellular single-unit recordings were made from
CeA neurons in anesthetized adult male rats before and during the development of an acute
arthritis. Arthritis was induced in one knee joint by intraarticular injections of kaolin and
carrageenan. Brief (15 s) mechanical stimuli of innocuous (100–500 g/30 mm2) and noxious (1000–
2000 g/30 mm2) intensity were applied to the knee and other parts of the body. In agreement with
our previous studies, all CeA neurons developed increased background and evoked activity after
arthritis induction. Ro-256981 (1, 10 and 100 μM; 15 min each) was administered into the CeA by
microdialysis 5–6 h postinduction of arthritis. Ro-256981 concentration-dependently decreased
evoked responses, but not background activity. This pattern of effect is different from that of an
NMDA receptor antagonist (AP5) in our previous studies. AP5 (100 μM – 5 mM) inhibited
background activity and evoked responses. The differential effects of AP5 and Ro-256981 may
suggest that NMDA receptors containing the NR2B subunit are important but not sole
contributors to pain-related changes of CeA neurons.
Background
Functional NMDA receptors are heteromeric assemblies
of NR1 subunits with NR2A-D or, less commonly, with
NR3A, B subunits [1-7]. The NR1 subunit is essential for
channel formation, Ca2+  permeability and voltage-
dependent Mg2+ block, whereas NR2 subunits form the
glutamate binding site and account for kinetic properties.
NR2B-containing NMDA receptors have slower kinetics
than those that include NR2A [8]. During development
NR2B expression is gradually replaced with NR2A in most
CNS neurons but not in the central nucleus of the amy-
gdala (CeA) [9]. NR2B containing receptors have been
implicated in synaptic plasticity, memory formation and
pain modulation [see [10]].
NMDA receptor function in the CeA is increased in a
model of arthritis pain [11,12]. NMDA receptor function
can be modulated through phosphorylation of NR1 or
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NR2 subunits by various kinases, including PKA, PKC,
ERK and tyrosine kinase [7,13-17]. Our previous studies
showed that PKA-dependent phosphorylation of NR1 in
the CeA is a key mechanism of increased responsiveness
and synaptic plasticity in the arthritis pain model [11,12].
ERK activation also increases NMDA receptor function in
the CeA, but PKC does not seem to be involved [18]. PKA
activation appears to be downstream of CGRP1 receptors
[19] and CRF1 receptors)[20,21]. NMDA receptors in the
CeA do not contribute significantly to normal synaptic
transmission and the processing of physiological nocicep-
tive inputs [11,12]. The role of NR2B subunits in pain-
related changes of CeA neurons is not known.
Findings
Extracellular single-units were made from 8 neurons in
the laterocapsular division of the CeA in 8 anesthetized
male rats (250–350 g) as described in detail
before)[21,22]. All experimental procedures were
approved by the Institutional Animal Care and Use Com-
mittee (IACUC) at the University of Texas Medical Branch
and conform to the guidelines of the International Associ-
ation for the Study of Pain (IASP) and of the National
Institutes of Health (NIH). Animals were mounted in a
stereotaxic frame, paralyzed with pancuronium (induc-
tion: 0.3–0.5 mg, i.v.; maintenance: 0.3 mg/h, i.v.) and
artificially ventilated (3–3.5 ml; 55–65 strokes/min).
Constant levels of anesthesia were maintained by contin-
uous i.v. infusion of pentobarbital (15 mg/kg per h). A
small unilateral craniotomy was performed at the sutura
frontoparietalis level for the recording of CeA neurons
with glass-insulated carbon filament electrodes and for
drug application by microdialysis (CMA11/Microdialysis
Inc., North Chelmsford, MA; 8 kD cut-off, membrane
diameter: 250 μm, membrane length: 1 mm). The follow-
ing stereotaxic coordinates were used [23]: recording elec-
trode, 2.1–2.8 mm caudal to bregma; 3.8–4.2 mm lateral
to midline; depth 7–9 mm; microdialysis probe, 1.8 mm
caudal to bregma; 4.0 mm lateral to midline; depth of tip
9.0 mm.
Background activity and responses evoked by brief (15 s)
mechanical test stimuli of increasing intensities (100,
500, 1000, 1500 and 2000 g/30 mm2 force, applied with
a calibrated forceps at 15 s interstimulus intervals; see Fig.
1) were recorded before and after induction of a knee joint
arthritis with intraarticular injections of kaolin and carra-
geenan [24]. Stimulus intensities of 100 and 500 g/30
mm2 applied to the knee and other deep tissue are consid-
ered innocuous, whereas intensities of >1500 g/30 mm2
are noxious because they evoke withdrawal reflexes and
vocalizations in awake rats [25]. Background activity
before stimulation was subtracted from the total response
during stimulation to calculate the net response evoked
by a particular stimulus.
In this study neurons were selected which had a receptive
field in the knee and responded more strongly to noxious
than innocuous stimuli. These so-called multireceptive
(MR) neurons, and only MR neurons, become sensitized
consistently in the arthritis pain model [11,19,22,26]. Fig-
ures 1 and 2 show individual examples. Background activ-
ity and evoked responses are enhanced after arthritis
induction (Fig. 1B). Figure 2 illustrates the time course of
pain-related changes. Responses to innocuous (500 g/30
mm2) and noxious (2000 g/30 mm2) stimulation (com-
pression) of the knee (Fig. 2A) and background activity
(Fig. 2B) increased within few hours after arthritis induc-
tion and reached a maximum plateau at 5 h postinduc-
tion.
A potent and selective NR2B receptor antagonist (Ro-
256981) [27,28] was administered into the CeA through
a microdialysis probe that had been inserted stereotaxi-
cally several hours before the experiment. Artificial cere-
brospinal fluid (ACSF) was pumped through the fiber at a
rate of 5 μl/min throughout the experiment to maintain
stable conditions in the tissue. Ro-256981 (R-R*, S*)-α-
(4-hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperi-
dine propanol) was a gift from Gedeon Richter Ltd., Buda-
pest, Hungary. Ro-256981 was dissolved in water to
obtain stock solutions (10 mM). Stock solutions were
diluted in ACSF to their final concentrations on the day of
the experiment. Drug concentrations in the microdialysis
fiber were 1.0, 10 and 100 μM, i.e., 100 times that pre-
dicted to be needed in the tissue based on data in the lit-
erature [27], because of the concentration gradient across
the dialysis membrane [11,22,29]. Ro-256981 was only
tested in the arthritis state because NMDA receptor antag-
onists have little or no effect on CeA neurons under nor-
mal conditions [11,12].
Administration of different concentrations (15 min each)
of Ro-256981 into the CeA 5–6 h postinduction of arthri-
tis decreased the evoked responses but not background
activity (see individual examples in Figs. 1 and 2). The
effects of Ro-256981 were concentration-dependent (Fig.
3; n = 8 neurons) and partially reversible after washout in
ACSF for >30 min (Fig. 1D and Fig. 2A). Concentrations
of 10 μM and 100 μM had significant effects (P < 0.05–
0.001, Dunnett's multiple comparison test comparing the
effects of individual concentrations of Ro-256981 to pre-
drug control values). Non-linear regression analysis
yielded apparent IC50 values of 7.9 μM and 9.3 μM for the
inhibition of responses to normally innocuous and nox-
ious stimuli, respectively.
Considering the concentration gradient across the dialysis
membrane and diffusion in the tissue, these IC50 values
are consistent with reported Kd values of 3 nM for the
high-affinity binding Ro-256981 to rat forebrain mem-Molecular Pain 2009, 5:21 http://www.molecularpain.com/content/5/1/21
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Ro-256981 inhibits pain-related sensitization of an individual amygdala neuron Figure 1
Ro-256981 inhibits pain-related sensitization of an individual amygdala neuron. Extracellular recordings of the 
responses (spikes/s) of one CeA neuron to brief (15s) graded mechanical stimulation (compression) of the knee. (A) In the 
control period before arthritis, the neuron responded more strongly to noxious than to innocuous stimuli. (B) The responses 
of the same neuron increased 5 h after induction of the arthritis in one knee. (C) Administration of Ro-256981 (10 μM, con-
centration in the microdialysis probe; 15 min) into the CeA inhibited the increased responses. (D) The inhibitory effect of Ro-
256981 was largely reversible after wash out with ACSF for 30 min. (A-D) Top traces show recordings of the force (g/30 mm2) 
applied to the knee joint with a calibrated forceps. Peristimulus time histograms show number of action potentials (spikes) per 
second. Insets show that spike size and configuration remained constant throughout the experiment.
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Time course of the effects of arthritis and Ro-256981 in an individual amygdala neuron Figure 2
Time course of the effects of arthritis and Ro-256981 in an individual amygdala neuron. The responses of the CeA 
neuron to innocuous (500 g/30 mm2) and noxious (2000 g/30 mm2) stimulation of the knee (A) and background activity (B) 
increased after induction of the knee joint arthritis Administration of Ro-256981 (1, 10, and 100 μM; concentration in the 
microdialysis probe; 15 min) into the CeA reduced the enhanced responses (A) but not background activity (B) in a concentra-
tion-dependent fashion. Symbols show the mean activity during a 15 s period before stimulation (= background activity, B) and 
the difference between mean activity during and before 15 s stimuli (= net activity evoked by noxious or innocuous stimuli, A). 
Artificial cerebrospinal fluid (ACSF) was administered as a vehicle control before and after drug application.
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branes that contain different NMDA receptor subtypes
[27]. They are also consistent with IC50 values for inhibi-
tory effects of Ro-256981 on membrane currents evoked
in oocytes coexpressing NR1C and NR2B (9 nM) or NR1F
and NR2B (17 nM) and on NMDA-induced membrane
currents in cultured rat cortical neurons expressing NR2B
as the dominant NR2 subunit (15 nM) [27]. The selectiv-
ity of Ro-256981 for NR2B over NR2A is about 5000-fold
[27].
Our data show that the endogenous activation of NR2B-
containing receptors contributes critically to the increased
evoked responses, but not background activity, of CeA
neurons observed in the arthritis pain model. The diag-
nostic NMDA receptor antagonist AP5 inhibited evoked
responses and background activity of CeA neurons in this
pain model [11]. Furthermore, the effects of AP5 were
greater on responses evoked by low- than high-intensity
stimulation [11]. The differential effects of Ro-256981
and AP5 may suggest the involvement of other NMDA
subtypes.
Accumulating evidence implicates NR2B-containing
NMDA receptors in pain mechanisms and pain behavior.
Systemic application of NR2B-selective antagonists such
as CP-101,606 and Ro-256981 had antinociceptive effects
in models of inflammatory and neuropathic pain
[28,30,31]. Ro-256981 applied systemically or injected
into the anterior cingulate cortex (ACC) inhibited allody-
nia-like behavior of mice in an inflammatory pain model
[32]. Ro-256981 also decreased NMDA receptor-medi-
ated synaptic currents in ACC neurons in slices from mice
with hindpaw inflammation and this effect was greater
than in slices from control mice [32]. Spinal administra-
tion of Ro-256981 decreased the responses of spinal dor-
sal horn neurons to electrical C-fiber stimulation and
attenuated C-fiber evoked long-term potentiation [33].
Hindpaw inflammation increased the expression of
NR2B, but not NR1 or NR2A, in the ACC [32] and
increased tyrosine phosphorylation of NR2B, but not
NR2A, in the spinal cord [34,35] but not ACC [32]. Over-
expression of NR2B in the ACC and insular cortex of trans-
genic mice resulted in prolonged nocifensive behavior in
the formalin pain test without altering acute nocifensive
responses [36].
Conclusion
This study shows for the first time that NR2B receptor acti-
vation in the amygdala (CeA) contributes to pain-related
increases of responsiveness of CeA neurons in the arthritis
pain model. Administration of a selective NR2B receptor
antagonist (Ro-256981) into the CeA decreased evoked
responses but not background activity of CeA 5–6 h
postinduction of arthritis. The differential effects of Ro-
256981 and the diagnostic NMDA receptor antagonist
(AP5) measured in our previous study [11] suggest that
other NMDA receptor subtypes may be involved as well.
In agreement with previous studies in the spinal cord and
anterior cingulate cortex (ACC), these results provide fur-
ther evidence for an important role of NR2B in pain-
related neuroplasticity.
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Concentration-dependent inhibitory effects of Ro-256981 in  the arthritis pain model Figure 3
Concentration-dependent inhibitory effects of Ro-
256981 in the arthritis pain model. Administration of 
Ro-256981 into the CeA 5–6 h postinduction of arthritis 
inhibited the responses of CeA neurons (n = 6–8 neurons for 
each concentration) to normally innocuous and noxious 
stimuli but not background activity. Numbers refer to the 
concentrations in the microdialysis probe (MD). Ro-256981 
was administered into the CeA by microdialysis for 15 min. 
All averaged values are given as the mean ± SEM and are 
expressed as percent of predrug control values (in ACSF; set 
to 100%). The following formula was used for non-linear 
regression analysis to obtain concentration-response curves 
and calculate IC50 values: y = A+(B-A)/[1+(10C/10X)D], where 
A is the bottom plateau, B top plateau, C = log(IC50), and D is 
the slope coefficient (Prism 3.0, GraphPad Software). * P < 
0.05, ** P < 0.01, *** P < 0.001, compared to predrug control 
values (Dunnett's multiple comparison test).
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